N-Oleoyl leucine is an N-acyl amide generated by PM20D1 that uncouples mitochondrial respiration independent of uncoupling protein 1 (UCP1) in vitro. N-Oleoyl leucine (25 mg/kg, i.p.) decreases body weight and food intake, preferentially decreasing fat mass in a diet-induced obesity mouse model. It improves glucose homeostasis in a fasting glucose tolerance test and increases VO2 while slightly decreasing overall locomotor activity.
N-Oleoyl leucine is an N-acyl amide generated by PM20D1 that uncouples mitochondrial respiration independent of uncoupling protein 1 (UCP1) in vitro. N-Oleoyl leucine (25 mg/kg, i.p.) decreases body weight and food intake, preferentially decreasing fat mass in a diet-induced obesity mouse model. It improves glucose homeostasis in a fasting glucose tolerance test and increases VO2 while slightly decreasing overall locomotor activity.
Shipping & Handling
Shipped In
Wet ice in continental US; may vary elsewhere
Safety & Storage
Storage Temperature
-20°C
Safety Statement
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
WARNING This product is not for human or veterinary use. Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Regulatory & Compliance
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.
We’re currently in BETA - Interested in joining? Let us know and we’ll get you set up with early access.